Back

Ketamine-induced NMDA receptor hypofunction alters social and locomotor behavior in adult zebrafish

Gallas-Lopes, M.; Muller, D. V.; Stahlhofer-Buss, T.; Bastos, L. M.; Becker, S. Z.; Bruck, S. M.; Piato, A.; Herrmann, A. P.

2025-09-17 pharmacology and toxicology
10.1101/2025.09.16.676572 bioRxiv
Show abstract

BackgroundNMDA receptor antagonists, such as ketamine, are widely used to model schizophrenia-related phenotypes in preclinical studies. While zebrafish have emerged as a promising model organism for neuropsychiatric research, few studies have characterized their behavioral responses to repeated ketamine exposure. MethodsThree independent experiments were conducted to evaluate the acute, repeated and sustained behavioral effects of ketamine in adult zebrafish. In Experiment I, fish were exposed to 10, 20, or 40 mg/L ketamine once daily for five days, and submitted to the social preference (SPT) and open tank (OTT) tests on days 1 and 5, and re-exposed and re-tested on day 7 after a 48-hour washout. Experiments II and III assessed whether behavioral changes persisted following 5- or 14-day exposure protocols, with testing conducted 48 hours after the final treatment. ResultsKetamine induced robust, concentration-dependent alterations in Experiment I: it reduced social interaction and increased locomotor activity in the SPT on all experimental days, while increased rotational behavior in the OTT on days 1 and 5. These effects did not intensify over repeated exposure and were not sustained after a 48-hour washout in either protocol (Experiments II and III). ConclusionsThe results support the utility of zebrafish for modeling acute behavioral responses to NMDA receptor antagonism, capturing features of schizophrenia-like phenotypes. However, no evidence of behavioral sensitization or lasting disruption was observed, diverging from rodent studies. Future studies should incorporate antipsychotic validation, neurochemical analyses, and alternative exposure strategies to further develop zebrafish as a translational model for psychiatric research.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Frontiers in Psychiatry
83 papers in training set
Top 0.1%
14.9%
2
Journal of Psychopharmacology
14 papers in training set
Top 0.1%
8.5%
3
PLOS ONE
4510 papers in training set
Top 27%
6.4%
4
Drug and Alcohol Dependence
37 papers in training set
Top 0.2%
6.4%
5
Frontiers in Pharmacology
100 papers in training set
Top 0.5%
4.9%
6
Neuropsychopharmacology
134 papers in training set
Top 0.7%
4.2%
7
Psychopharmacology
59 papers in training set
Top 0.2%
3.9%
8
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.1%
3.6%
50% of probability mass above
9
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
62 papers in training set
Top 0.4%
3.6%
10
Translational Psychiatry
219 papers in training set
Top 2%
2.8%
11
Pharmacology Biochemistry and Behavior
17 papers in training set
Top 0.1%
2.5%
12
Schizophrenia Research
29 papers in training set
Top 0.3%
2.1%
13
Epilepsia
49 papers in training set
Top 0.4%
2.1%
14
The British Journal of Psychiatry
21 papers in training set
Top 0.4%
2.1%
15
Journal of Psychiatric Research
28 papers in training set
Top 0.3%
1.9%
16
Brain, Behavior, and Immunity
105 papers in training set
Top 1%
1.9%
17
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.4%
1.7%
18
Scientific Reports
3102 papers in training set
Top 57%
1.7%
19
BMJ Open
554 papers in training set
Top 9%
1.7%
20
British Journal of Pharmacology
34 papers in training set
Top 0.2%
1.5%
21
Neuropharmacology
60 papers in training set
Top 0.5%
1.3%
22
Schizophrenia Bulletin
29 papers in training set
Top 0.5%
1.3%
23
Biological Psychiatry Global Open Science
54 papers in training set
Top 1%
1.1%
24
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 0.7%
1.0%
25
Molecular Psychiatry
242 papers in training set
Top 3%
0.9%
26
European Neuropsychopharmacology
15 papers in training set
Top 0.6%
0.8%
27
Psychiatry and Clinical Neurosciences
11 papers in training set
Top 0.4%
0.8%
28
JMIR Formative Research
32 papers in training set
Top 2%
0.8%
29
JAMA Psychiatry
13 papers in training set
Top 0.6%
0.8%
30
Psychiatry Research
35 papers in training set
Top 2%
0.7%